CoLucid Pharmaceuticals (CLCD) PT Raised to $30 at Stifel

September 19, 2016 9:04 AM EDT
Get Alerts CLCD Hot Sheet
Price: $34.80 -0.91%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade CLCD Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Stifel analyst Annabel Samimy reiterated a Buy rating and bumped her price target on CoLucid Pharmaceuticals (NASDAQ: CLCD) to $30.00 (from $27.00) after the company reported additional data from its Phase 3 SAMURAI trial of lasmiditan in acute migraine. In addition to meeting all of its primary endpoints, lasmiditan demonstrated high statistical significance on most of its secondary endpoints, including: 1) headache relief at 2 hours, 2) headache freedom two hours after dosing when used as a second dose for rescue or recurrence, 3) the efficacy of lasmiditan on the Patient Global Impression of Change (PGIC), and 4) efficacy of lasmiditan based on migraine disability at 2 hours. Lasmiditan also achieved statistical significance on freedom from Most Bothersome Symptom (MBS) with the majority of patients choosing photophobia as MBS at baseline. On safety, the full data confirmed lasmiditan did not result in an increase in AEs or cardiovascular risk on the second dose.

Samimy commented, "Overall, we believe these data confirm the strong profile of lasmiditan on both efficacy and safety, and see the drug appropriate for a broad migraine patient population despite its specific utility in CV patients. Reiterate Buy, bumping up TP to $30."

For an analyst ratings summary and ratings history on CoLucid Pharmaceuticals click here. For more ratings news on CoLucid Pharmaceuticals click here.

Shares of CoLucid Pharmaceuticals closed at $28.13 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities


Add Your Comment